Luke Miels
Coverage of Luke Miels in the Nexus archive.
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker GSK, led by new CEO Luke Miels, has agreed to acquire US-based cancer treatment firm Nuvalent for $10.6 billion. The deal aims to strengthen GSK's oncology portfolio, with Nuvalent developing three late-stage lung cancer medications.
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker GSK has agreed to acquire US-based cancer treatment company Nuvalent for $10.6 billion to expand its oncology portfolio. The deal includes Nuvalent's three late-stage lung cancer medications.
- GSK reports promising early results in ovarian and womb cancer drug trial
GSK reported early trial results showing Mo-Rez reduced or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients. The CEO, Luke Miels, is advancing drug development efforts for the potential blockbuster treatment.